Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer

被引：29

作者：

Morton, Magda ^{[1
]}

Prendergast, Clodagh ^{[1
]}

Barrett, Terrance D. ^{[1
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2011年 / 32卷 / 04期

关键词：

RECEPTOR ANTAGONIST; COLORECTAL-CANCER; OMEPRAZOLE TREATMENT; B/GASTRIN RECEPTOR; CCK2; RECEPTOR; IN-VIVO; CHOLECYSTOKININ; SECRETION; POTENT; HISTAMINE;

D O I：

10.1016/j.tips.2011.02.003

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Gastrin, acting through peripheral cholecystokinin (CCK) 2 receptors, is a major hormonal regulator of gastric acid secretion. The effects of gastrin on acid secretion occur both acutely and chronically because gastrin directly stimulates gastric acid secretion and also exerts trophic effects on the enterochromaffin-like and parietal cells that together constitute the acid secretory apparatus of the stomach. Several antagonists that target the CCK2 receptor have been identified and investigated for the treatment of gastroesophageal reflux disease and pancreatic cancer. In this paper, we discuss the contribution of gastrin to these disease pathologies and the data generated to date from clinical studies investigating CCK2 receptor antagonists.

引用

页码：201 / 205

页数：5

共 56 条

[1]

THE ROLE OF GASTRIN AND CHOLECYSTOKININ IN NORMAL AND NEOPLASTIC GASTROINTESTINAL GROWTH [J].

BALDWIN, GS .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1995, 10 (02) :215-232

[2]

A SINGLE AMINO-ACID OF THE CHOLECYSTOKININ-B GASTRIN RECEPTOR DETERMINES SPECIFICITY FOR NONPEPTIDE ANTAGONISTS [J].

BEINBORN, M ;

LEE, YM ;

MCBRIDE, EW ;

QUINN, SM ;

KOPIN, AS .

NATURE, 1993, 362 (6418) :348-350

[3]

Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans [J].

Beltinger, J ;

Hildebrand, P ;

Drewe, J ;

Christ, A ;

Hlobil, K ;

Ritz, M ;

D'Amato, M ;

Rovati, L ;

Beglinger, C .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1999, 29 (02) :153-159

[4]

A Life in New Drug Research [J].

Black, James .

BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 :S15-S25

[5]

Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer [J].

Black, James W. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (03) :360-364

[6]

DEFINITION AND ANTAGONISM OF HISTAMINE H2-RECEPTORS [J].

BLACK, JW ;

PARSONS, EM ;

DURANT, CJ ;

DUNCAN, WAM ;

GANELLIN, CR .

NATURE, 1972, 236 (5347) :385-&

[7]

Boyce M, 2000, BR J CLIN PHARM, V49, p493P

[8]

BOYCE M, 2000, BR J CLIN PHARM, V50, pP383

[9]

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[10]

A POTENT NONPEPTIDE CHOLECYSTOKININ ANTAGONIST SELECTIVE FOR PERIPHERAL-TISSUES ISOLATED FROM ASPERGILLUS-ALLIACEUS [J].

CHANG, RSL ;

LOTTI, VJ ;

MONAGHAN, RL ;

BIRNBAUM, J ;

STAPLEY, EO ;

GOETZ, MA ;

ALBERSSCHONBERG, G ;

PATCHETT, AA ;

LIESCH, JM ;

HENSENS, OD ;

SPRINGER, JP .

SCIENCE, 1985, 230 (4722) :177-179

← 1 2 3 4 5 6 →